Browse the evidence

There is insufficient evidence to support a causal relationship between GLP-1 receptor agonists and the risk of other common mental illnesses, including ADHD, Anorexia Nervosa, Autism Spectrum Disorder, and PTSD.

Based on this genetic study, GLP-1 drugs do not appear to reduce the risk of ADHD, Anorexia, Autism, or PTSD. Patients with these conditions should not rely on GLP-1 medications as a treatment for their mental health symptoms. Further research is needed to confirm these negative findings.

Current clinical practice for prescribing semaglutide for weight loss lacks comprehensive pretreatment screening for thyroid, pancreatic, and retinal risks, exposing patients to severe adverse outcomes.

If you are starting semaglutide for weight loss, ensure your doctor checks your calcitonin, pancreatic enzymes (lipase/amylase), and family history of thyroid cancer before starting. Standard blood tests are not enough to rule out serious risks associated with this medication.

For individuals with obesity who fail to lose ≥2% body weight in the first 4 weeks of intensive behavioral treatment, adding phentermine (15.0 mg/day) significantly increases 24-week weight loss compared to continuing behavioral treatment with placebo.

If you have been doing intensive lifestyle changes for a month and haven't lost at least 2% of your body weight, adding phentermine (15 mg daily) to your plan can significantly boost your weight loss results compared to sticking with lifestyle changes alone. This approach helps early non-responders achieve clinically meaningful weight loss (≥5%) much more effectively. Regular monitoring of blood pressure and heart rate is recommended due to potential side effects.

Subcutaneous semaglutide (2.0 mg or higher, once weekly) produces significant weight loss and cardiometabolic improvements in adults with overweight or obesity, with efficacy increasing in patients with Class II obesity and higher dosages.

If you have overweight or obesity, subcutaneous semaglutide taken once weekly at a dose of 2.0 mg or higher is a highly effective treatment for weight loss. It works best when combined with lifestyle changes (diet and exercise). You can expect significant weight loss (nearly 9 kg on average in this analysis) and improvements in waist circumference and BMI. Patients with more severe obesity (Class II) tend to lose more weight. While gastrointestinal side effects like nausea are common, serious side effects are rare. The once-weekly schedule is preferred for adherence and safety over daily dosing.

AMG 133 (maridebart cafraglutide), a bispecific molecule combining a GIP receptor antagonist with a GLP-1 receptor agonist, produces pronounced, dose-dependent weight loss and improves metabolic parameters in adults with obesity.

AMG 133 is a new injectable medication for obesity that works by targeting two gut hormones (GLP-1 and GIP). In early clinical trials, it caused significant weight loss (up to 14.5% of body weight) with a dosing schedule of just one injection every four weeks. While it can cause temporary nausea or vomiting, these side effects are usually mild and go away quickly. It is currently in clinical trials and not yet widely available.

High-intensity interval training (HIIT) significantly improves insulin sensitivity (fasting insulin and HOMA-IR) and cardiorespiratory fitness (VO2max) compared to moderate-intensity continuous training (MICT) in patients with diabesity.

If you have type 2 diabetes and are overweight, High-Intensity Interval Training (HIIT) may offer better improvements in insulin sensitivity and heart health than steady-state moderate exercise. HIIT involves short bursts of effort exceeding 80% of your max heart rate. It is time-efficient and can be adapted to your fitness level, making it a viable option even if you have physical limitations.

In patients with diabesity who have comorbidities, HIIT may significantly increase HDL cholesterol and further reduce HOMA-IR compared to MICT.

If you have type 2 diabetes, obesity, and other health conditions, HIIT might offer extra benefits for your 'good' cholesterol (HDL) and insulin resistance compared to moderate exercise. However, the evidence for this is very low certainty.

Among GLP-1 receptor agonists, Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide and Liraglutide in post-bariatric surgery patients, with the lowest rate of non-responders.

If you are using a GLP-1 agonist after bariatric surgery and not seeing enough results, ask your doctor about switching to or starting Tirzepatide. It is a newer dual-agonist that has shown greater weight loss and fewer non-responders compared to older options like Liraglutide or Semaglutide in recent studies. Note that data is currently limited to shorter-term studies.

High-intensity interval training (HIIT) significantly improves cardiometabolic health markers—including glycemic control, insulin resistance, and lipid profiles—in patients with diabesity (Type 2 Diabetes and Obesity), even when body composition changes are minimal.

If you have Type 2 Diabetes and are overweight, High-Intensity Interval Training (HIIT) is a highly effective way to improve your blood sugar and cholesterol levels, even if the scale doesn't move much. Aim for short, intense bursts of exercise (like cycling or walking) 3 times a week for about 20-30 minutes, interspersed with rest. This approach targets your metabolic health directly and is considered safe for this population when prescribed correctly.

HIIT significantly improves lipid profiles (LDL, Triglycerides, Total Cholesterol) and insulin resistance (HOMA-IR) in patients with diabesity.

Focus on improving your insulin sensitivity and cholesterol through HIIT. This type of training has been shown to significantly lower your HOMA-IR score and improve LDL and Triglyceride levels compared to doing nothing, offering a powerful metabolic boost for those with diabesity.

Once-daily oral orforglipron significantly reduces body weight, BMI, and waist circumference compared to placebo in adult patients with obesity or overweight.

Take once-daily oral orforglipron as prescribed. Expect an average weight loss of about 6 kg compared to placebo, along with improvements in waist circumference and metabolic markers. Be prepared for common, non-severe gastrointestinal side effects like nausea, but note that serious adverse events are not increased. This is a viable alternative to injectable GLP-1s for those who prefer oral medication.

Postoperative use of GLP-1 receptor agonists (specifically liraglutide and semaglutide) effectively treats suboptimal clinical response (SoCR) and recurrent weight gain (RWG) after metabolic bariatric surgery, achieving weight loss comparable to or exceeding non-surgical populations.

If you regain weight after bariatric surgery, do not assume you must have another operation. GLP-1 medications (like semaglutide or liraglutide) are highly effective at reversing weight regain and improving metabolic health, often working better than in non-surgical patients.

Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks reduces medication costs by approximately 50% while maintaining 70-75% of the weight loss efficacy.

If you are on a GLP-1 medication like semaglutide or tirzepatide and cost is a major barrier, discuss with your doctor the possibility of extending your dosing interval (e.g., from once a week to once every two weeks). While you might not lose as much weight as the maximum possible, you will likely retain most of the benefit (around 75%) while cutting your medication costs in half. This is particularly useful for ensuring long-term access to the medication.

Semaglutide administration (0.5-1 mg weekly) enables obese end-stage renal disease (ESRD) patients on hemodialysis to achieve target BMI and become eligible for renal transplantation with substantial weight loss (11.7-14.8%) and minimal side effects.

If you have end-stage kidney disease and are on dialysis, obesity might currently block you from getting a transplant. This case series suggests that using semaglutide (a weekly injection) can help you lose enough weight (around 12-15% of body weight) to meet transplant criteria. It was well-tolerated in these patients, but requires close monitoring by your nephrologist to adjust dialysis settings as you lose weight. It serves as a bridge to surgery when lifestyle changes or bariatric surgery are not options.

GLP-1 analogues (liraglutide and semaglutide) enable significant weight loss (approx. 14%) in obese patients with end-stage lung disease, thereby bridging the gap to lung transplantation eligibility when dietary and exercise interventions fail.

If you have severe lung disease and a BMI that bars you from transplant, ask your care team about GLP-1 medications (like semaglutide or liraglutide). This case shows they can help you lose enough weight to qualify for surgery when diet and exercise aren't enough, even while taking steroids.

Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks maintains approximately 70-75% of the weight loss efficacy while reducing total drug cost by 50%.

If you are taking a GLP-1 drug like semaglutide or tirzepatide, ask your doctor about extending your dosing interval to every two weeks. Mathematical models suggest this could cut your medication costs by 50% while keeping about 75% of the weight loss benefits. This is not a substitute for medical advice, but it is a potential strategy to improve affordability and adherence.

For patients on lower doses of tirzepatide (e.g., 5 mg), switching to a less frequent dosing schedule (e.g., every two weeks) while simultaneously increasing the dose size (e.g., to 10 mg or 15 mg) can maintain or even exceed the weight loss efficacy of the standard once-weekly regimen.

If you are on a lower dose of tirzepatide (5 mg) and find it expensive, ask your doctor if switching to a higher dose (10 mg or 15 mg) taken every two weeks is an option. This strategy might keep your weight loss results the same or even better while cutting your costs in half. However, be aware that higher doses may increase side effects, so this requires careful medical supervision.

GLP-1 receptor agonists have assumed the primary role in treating obesity with significant weight loss.

Practitioners should consider GLP-1 receptor agonists as a treatment for obesity.

Combination anti-obesity medication regimens including GLP-1 receptor agonists can achieve total body weight loss (approx. 32.5%) comparable to metabolic/bariatric surgery in patients with severe obesity.

If you have severe obesity and have not lost significant weight with standard medications or lifestyle changes alone, ask your doctor about combination therapy. Adding a GLP-1 agonist (like semaglutide) to other approved weight-loss drugs may produce results similar to bariatric surgery. This approach targets multiple biological pathways (hunger, satiety, metabolism) simultaneously, which may be necessary for severe cases.

Traditional Chinese Medicine (TCM) interventions, including acupuncture, herbal medicine, and dietary therapy, may help manage obesity and diabetes by regulating gut microbiota, reducing inflammation, and improving insulin sensitivity.

If you are managing obesity or diabetes, TCM modalities like acupuncture, specific herbal formulas (e.g., Ginseng, Cinnamon), and dietary adjustments may offer supportive benefits by improving insulin sensitivity and gut health. However, these should not replace standard lifestyle changes or prescribed medications without consulting your doctor, as the evidence is still evolving.

Soy protein supplementation has an inconsistent effect on testosterone and cortisol levels, and more research is required to determine its impact on anabolic hormones.

Don't worry about soy protein affecting your hormones. The research shows inconsistent effects on testosterone and cortisol, with no clear evidence of negative impacts. You can consume soy protein without fear of hormonal disruption.

Newer GLP-1/GIP receptor agonists (semaglutide, tirzepatide) are expected to provide superior post-operative weight loss compared to prior GLP-1 RAs, despite a lack of specific post-surgical clinical trials.

Semaglutide and tirzepatide show impressive weight loss in non-surgical patients, but there is currently no data on their effectiveness specifically after bariatric surgery. Liraglutide and topiramate remain the best-supported options for post-surgical weight regain.

GLP-1 receptor agonists and GIP may influence cardiac lipid metabolism by modulating LPL activity, potentially offering cardioprotection, though the specific effect on cardiac LPL remains unclear.

GLP-1 and GIP drugs help with weight and glucose, but they may also directly affect how the heart processes fat. The exact impact on the heart is still being studied, but it may offer additional protection beyond weight loss.

Semaglutide treatment (up to 2.4 mg weekly) significantly reduces body weight, fat mass, and emotional eating behaviors in patients with hypothalamic obesity resulting from craniopharyngioma.

For patients with hypothalamic obesity due to brain tumors or surgery, semaglutide (up to 2.4 mg/week) combined with dietary counseling can significantly reduce weight and emotional eating, even when other treatments fail. It works by targeting brain circuits beyond the damaged hypothalamus.